Atherosclerosis involves a specialized inflammatory process regulated by an intricate network of cytokine and chemokine signaling. Atherosclerotic lesions lead to the release of cytokines that can have multiple affects on various vascular cell functions either promoting lesion expansion or alternatively retard progression. Tumor necrosis factor-a (TNF-a) is one such cytokine that can activate both cell survival and cell death mechanisms simultaneously. Here we show that TNF-a induces apoptosis in human aortic endothelial cells (HAECs), while it promotes the proliferation of vascular smooth muscle cells (VSMCs). Both events involved the activation of the Rb-E2F1 transcriptional regulatory pathway. Stimulation of HAECs with TNF-a led to an increased expression of p73 protein and a reduction in the levels of p53. This involved apoptosis signalregulating kinase 1 (ASK1)-mediated inactivation of Rb and its dissociation from the p73 promoter. In contrast, TNF-a stimulation of VSMCs enhanced the association of E2F1 with proliferative promoters like thymidylate synthase and cdc25A, while Rb was dissociated. ASK1 kinase has a critical role in the apoptotic process, as its depletion or dissociation from Rb reduced TNF-a-induced apoptosis. These results show that the cytokine TNF-a can elicit diametrically opposite responses in vascular endothelial cells and VSMCs, utilizing the Rb-E2F pathway.
Tumor necrosis factor-a (TNF-a) is an inflammatory cytokine that is known to have diverse and potentially conflicting roles in cardiac function and pathology. These include beneficial effects, such as cardioprotection against ischemia, as well as potentially adverse affects, such as development of atherosclerosis, reperfusion injury, hypertrophy and heart failure. TNF-a mediates inflammatory, proliferative, cytostatic and cytotoxic effects in multiple cell types, including endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). 1, 2 Apoptosis induced by TNF super family requires binding of the ligand to its receptor leading to oligotrimerization of receptors. [3] [4] [5] This results in aggregation of death domain containing proteins allowing recruitment of TRADD (TNF receptor 1-associated death domain protein). TRADD binds Fas associated death domain-containing protein and TNF receptor 1-associated protein 2 proteins, which in turn lead to activation of procaspase-8 and apoptosis signal-regulating kinase 1 (ASK1), respectively. [6] [7] [8] TNF-a treatment leads to the activation of the ASK1-JNK/p38 death signals. [8] [9] [10] Earlier studies from our laboratory had shown that the ASK1 kinase binds to Rb when cells encounter apoptotic stimuli like TNF-a or oxidative stress. 11 Overexpression of Rb abrogates ASK1-mediated apoptosis by inhibiting its pro-apoptotic activity, whereas activated ASK1 could phosphorylate and inactivate Rb. 11 Thus, ASK1-mediated inactivation of Rb is essential for its apoptotic activity in response to TNF-a.
Rb is believed to exert its anti-apoptotic functions by inhibiting the activity of E2F family of transcription factors, mainly E2F1. 12, 13 It is established that Rb physically interacts with E2F1 and represses its transcriptional activity; inactivation of Rb by phosphorylation disrupts the binding, releasing free, transcriptionally active E2F1. 12 Downstream targets of the E2F1 include genes involved in cell cycle progression (cyclin E, cdc25A and DNA polymerase a etc.), as well as proapoptotic genes (Apaf1, p73 and caspase 3 etc.). 14, 15 Inactivation of Rb during cell cycle progression leads to the expression of proliferative E2F1 targets whereas inactivation of Rb by apoptotic signals leads to the expression of pro-apoptotic genes.
E2F-1 can function as an oncogene or a tumor suppressor; 16 it can induce cell proliferation and transform cells, demonstrating its oncogenic properties, whereas E2F1 knockout mice developed tumors, suggesting tumor-suppressive properties. 17 Rb knockout mice die early during embryogenesis and display extensive apoptosis, whereas mouse embryos null for both Rb and E2F-1 display reduced apoptosis. E2F1 induces apoptosis through the p53 pathway or utilizes the p53-related p73 gene, which is a transcriptional target of E2F1. 18 TNF-a induces both apoptosis and G1 arrest in EC. Earlier studies have shown that the sensitivity of ECs to TNF-a is cell cycle-dependent and cytotoxicity is seen in proliferating cultures; starvation-synchronized or S-and G2/M-arrested ECs are resistant to TNF-a. It has been suggested that TNF-a inhibits E2F1 by preventing Rb phosphorylation. 19 Kishore et al. 20, 21 demonstrated that JNK1 and p38 MAPKs differentially affect TNF-a-mediated suppression of E2F1 in EC via two distinct and opposing mechanisms. In response to TNF-a, JNK physically associates with E2F1 and inactivates it via direct phosphorylation. In contrast, insufficient activation of p38 in TNF-a exposed EC results in reduced Rb phosphorylation and inactivation of E2F1. However, it is still unclear how TNF-a affects Rb-mediated E2F1 repression and causes apoptotic response in ECs.
Migration of VSMCs is a crucial event in the formation of vascular stenotic lesions and TNF-a modulates this process during atherosclerosis by inducing proliferative/pro-apoptotic responses in these cells. [22] [23] [24] However, there are conflicting reports on the effect of TNF-a on proliferation and apoptosis of VSMCs. 24 Several investigations report that TNF-a had no effect on VSMC proliferation, whereas other studies suggest that TNF-a induces proliferation of VSMCs through NF-kB. 25 Similarly, the pro-apoptotic activity for TNF-a in these cells has also been unclear. 26 Though E2F1 is known to mediate proliferation or cellular apoptosis, there is limited knowledge about its role in the cells involved in cardiovascular pathology. The data presented here suggest that TNF-a induces apoptosis in human aortic endothelial cells (HAECs) and proliferation in VSMCs using the Rb-E2F pathway. TNF-a-induced apoptosis involves the binding of ASK1 to Rb protein and induction of p73a gene in an E2F-dependent manner. Thus, it appears that differential effects of TNF-a on HAECs and VSMCs are mainly mediated through the Rb-E2F pathway.
Results
Apoptotic effects of TNF-a on ECs are mediated through ASK1 and p73. Attempts were made to evaluate the apoptotic or proliferative effect of TNF-a on primary human aortic ECs. Towards this purpose, HAECs were treated with 100 ng/ml TNF-a for 18 h; apoptosis was measured by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay. As shown in Figures 1a and b , 70±10.0 % (Po0.01) cells underwent apoptosis in response to TNF-a treatment. In a similar experiment, HAECs were treated with TNF-a and cell proliferation assessed by measuring BrdU incorporation ( Figures 1c and d) ; although asynchronous HAECs had 70 ± 8.1% BrdU-positive cells, only 30 ± 2.8% (Po0.01) cells showed BrdU-positive staining after TNF-a treatment, suggesting that TNF-a predominantly induces apoptosis in HAECs. Induction of apoptosis by TNF-a in HAECs was confirmed by PARP cleavage (Figure 1e ). Western blots were conducted for proteins known to be involved in TNF-a-induced apoptosis, including ASK1, E2F1, Rb, p53 and p73. Stimulating HAECs with TNF-a led to an induction of p73 (1.9-fold) and ASK1 (1.95-fold), while the levels of Rb and p53 were reduced by 0.6-fold and 0.4-fold, respectively. There was no significant change in the levels of E2F1 protein. There was a slight reduction in phospho-p53 (Ser46) levels with TNF-a, indicating that p53 may not be involved in this process (Figure 1e ). We next examined whether ASK1 activation was involved in TNF-a-induced apoptosis in HAEC cells. ASK1 was immunoprecipitated from untreated and TNF-a treated (30 min, 2 and 18 h) HAECs and in vitro kinase assay was conducted using myelin basic protein as the substrate. There was increased ASK1 kinase activity with TNF-a treatment at 30 min, 2 h and a marked increase at 18 h ( Figure 1f) .
As ASK1 activates both JNK and p38 MAP kinases by a site-specific Ser/Thr phosphorylation of their respective MKKs, 27 we examined the phosphorylation of p38 and JNK in HAECs stimulated with TNF-a. Both phospho-p38 (Thr180/ Tyr182) and phospho-JNK (Thr183/Tyr185) levels increased from 5 min to 15 min of TNF-a treatment, whereas total p38 and JNK levels remained unchanged (Figure 1g ). This indicates that active p38 and JNK kinases work in conjunction with ASK1 to induce apoptosis in HAECs.
Proliferative effects of TNF-a on VSMCs. To understand how TNF-a treatment affects primary human aortic smooth muscle cells (AoSMCs), they were treated with 100 ng/ml TNF-a for 18 h. TUNEL assays showed that only 10 ± 2.0% (Po0.05) cells were apoptotic (Figures 2a and b) , comparable to that observed in untreated control cells. BrdU incorporation assays showed that TNF-a treatment led to a 3-fold increase in the number of proliferating cells (Figures 2c and d) , in striking contrast to the effect of TNF-a on HAECs. Interestingly, western blots showed that TNF-a treatment led to an induction of E2F1 (2.45-fold), but a downregulation of its pro-apoptotic target, p73, by 0.5-fold (Figure 2e ). Unlike HAECs, there was no reduction in the levels of p53 or Rb; however, phospho-p53 (Ser46) was reduced. Further, ASK1 levels were not altered and there was no detectable PARP cleavage (Figure 2e ). ASK1 activation was also assessed in AoSMC cells upon TNF-a treatment; there was a significant reduction in ASK1 kinase activity at 18 h of TNF-a stimulation (Figure 2f) . Similarly, phospho-p38 and phospho-JNK levels decreased with TNF-a treatment, demonstrating that TNF-a does not induce apoptosis in AoSMC cells (Figure 2g) . It thus appears that TNF-a has opposite effects on different layers of blood vessels and these correlate with changes in the ASK1-Rb-E2F-p73 pathway.
Silencing of ASK1, E2F1 and p73 protects HAECs from TNF-a-induced apoptosis. Earlier studies on Ramos cells had suggested that ASK1 modulates E2F1 activity and p73 levels to facilitate apoptosis. 11 To examine the role of these proteins in TNF-a-induced apoptosis of HAECs, cells were transfected with siRNAs to E2F1, ASK1, Rb, p53, p73 or a non-targeting control siRNA. The transfected cells were treated with TNF-a (100 ng/ml) for 18 h and apoptosis was assessed by TUNEL staining. It was found that approximately 70±5.0% (Po0.01) of untransfected and control siRNA-transfected cells underwent apoptosis after TNF-a treatment (Figure 3a) . Silencing of E2F1 decreased apoptosis to 38±2.1% (Po0.01); similarly, silencing of ASK1 resulted in only 35±4.0% (Po0.01) apoptotic cells. However, depletion of Rb potentiated the apoptotic response to 95±3.8% (Po0.01). Silencing p53 did not cause a significant change in apoptotic response; on the contrary, cells deprived of p73 showed a marked decrease in apoptosis (o40 ± 1.8%; Po0.01) compared with control siRNA-transfected cells upon TNF-a stimulation, suggesting that ASK1, E2F1, Rb and p73 are key factors in mediating apoptosis induced by TNF-a in HAECs (Figure 3a) .
To further confirm the TUNEL data, we analyzed apoptosis by PARP cleavage in HAECs (Figures 3c-g ). Depletion of E2F1 in HAECs completely abrogated PARP cleavage (Figure 3c) . Similarly, depletion of ASK1 led to a reduction (0.2-fold) of uncleaved/cleaved PARP (Figure 3d ). Silencing Rb and p53, on the other hand, increased the levels of uncleaved/cleaved PARP ratio by 1.17-fold (Figure 3e ) and by 0.6-fold on TNF-a-induced PARP cleavage (Figure 3f ). PARP cleavage was almost completely abrogated in cells transfected with p73 siRNA (Figure 3g ). These results directly implicate E2F1, ASK1 and p73 in TNF-a-induced apoptosis in HAECs.
Silencing ASK1 reverses cytostatic effect of TNF-a on HAECs. As TNF-a has a cytostatic effect on HAECs as well, we examined how the above genes affected TNF-a-induced growth arrest. HAECs were transfected with specific siRNAs and treated with TNF-a (100 ng/ml) for 18 h; cell proliferation Stimulation with TNF-a leads to PARP cleavage and p73 upregulation confirming an apoptotic response (e). In vitro ASK1 kinase assay showing that TNF-a treatment, in particular at 18 h, leads to a strong phosphorylation of myelin basic protein (MBP) indicating ASK1 activation. Ponceau staining shows equal loading of the substrate MBP and ASK1 western blot shows equal ASK1 loading (f). Western blotting analysis shows induction of phospho-JNK and phospho-p38 at 5, 10 and 15 min of TNF-a stimulation, while total JNK and p38 levels remain the same (g) Figure 2 TNF-a is unable to induce apoptosis in AoSMCs as seen by TUNEL staining (a and b). TNF-a induces cell proliferation in AoSMCs as seen by BrdU incorporation. Error bars indicate standard deviations from two independent experiments (c and d). TNF-a treatment induces Rb phosphorylation in AoSMCs, however, there is no detectable PARP cleavage or change in p73 levels (e). In vitro ASK1 kinase assay showing that TNF-a treatment does not lead to phosphorylation of MBP at 18 h of stimulation. Ponceau staining shows equal loading of the substrate MBP and ASK1 western blot shows equal ASK1 loading (f). Western blotting analysis shows reduction in phospho-JNK and phospho-p38 from 5 to 15 min of TNF-a stimulation, while total JNK and p38 levels remain the same (g) was assessed by BrdU incorporation. Although 80 ± 2.0% (Po0.01) of untransfected and control siRNA-transfected cells showed BrdU incorporation, treatment with TNF-a decreased the number of S-phase cells to 43 ± 1.9% (Po0.01) ( Figure 3b ). As expected, abrogation of E2F1 decreased the number of proliferating cells to 20 ± 9.0% (Po0.05); interestingly, ASK1 depletion rescued the cells from the cytostatic influence of TNF-a ( Figure 3b ). Cells transfected with control siRNA showed only 43±1.9% (Po0.01) cells in S-phase, whereas TNF-a treatment of ASK1 depleted cells showed 65±5.0% (Po0.01) S-phase cells. Although nearly 100% cells showed S-phase entry on Rb siRNA transfection, it could not rescue the cells from cytostatic effect of TNF-a ( Figure 3b ). Abrogation of p53 and p73 decreased the number of cells undergoing proliferation in control as well as TNF-a-treated cells, suggesting a limited role for these proteins in proliferation. It is also possible that the DNp73 isoform might contribute to the proliferation, and depletion of this isoform by the pan-p73 siRNA affects proliferation. These results show that ASK1 kinase is a necessary intermediary for TNF-a-induced cell proliferation and apoptosis in HAECs.
TNF-a mediates apoptotic effects mainly through p73a in ECs. ECs showed a significant induction of p73 upon TNF-a treatment. As p73 gene expresses at least 35 different mRNA variants, of which 14 different isoforms have been described, 28 we decided to determine which specific isoform mediates apoptotic effects of TNF-a. p73a and p73b are well documented for their role in the induction of apoptosis and cell cycle arrest 28 and we focused on these two isoforms. Western blot analysis of HAECs treated with TNF-a for 18 h revealed a 2-fold induction of p73a but no change in p73b or DNp73a (Figure 4a ). To further verify the involvement of p73a, cells were transfected with either control siRNA or p73siRNA-2 followed by TNF-a treatment. p73siRNA-2 significantly silenced p73a and not p73b (Figure 4b ). p73a was induced 2.1-fold upon TNF-a treatment of control siRNAtransfected cells, but p73b was not induced in either control siRNA or p73siRNA-2 transfected cells (Figure 4c ). We also analyzed the levels of DNp73a in presence of TNF-a. The DNp73 proteins are amino-truncated proteins containing an N-terminal domain different from p73 isoforms and act in a dominant-negative manner.
28 DNp73a levels were marginally reduced (0.28-fold) upon TNF-a treatment of untransfected HAECs (Figure 4a ). p73siRNA-2 had no effect on DNp73a (Figure 4b ). DNp73a levels decreased (0.4-fold) in HAEC cells both in the presence and absence of p73a protein with TNF-a stimulation (Figure 4c ).
TUNEL assay demonstrated that TNF-a-induced apoptosis in control siRNA-transfected cells (62±0.7%; Po0.01), but significantly less in p73 siRNA-2-transfected HAECs Silencing of ASK1, E2F1 and p73 by siRNA protects in HAECs from TNF-a-induced apoptosis as detected by PARP cleavage, whereas silencing of Rb increases the apoptosis in these cells, p53 siRNA transfection has limited effect on these cells (c-g) (8.9 ± 2.19%, Po0.05) (Figure 4d ). Real-Time PCR experiments revealed that p73a, but not p73b, was induced upon TNF-a stimulation. Although there was a considerable reduction in p73a mRNA levels with p73 siRNA-2 transfection even after TNF-a treatment, p73b mRNA levels did not change (Figures 4e and f) . These results ascertain that p73a is the main mediator of apoptosis in HAECs upon TNF-a stimulation.
AoSMCs are resistant to TNF-a-induced apoptosis even after silencing of ASK1, E2F1, Rb, p53 and p73. We examined whether depletion of ASK1, E2F1, Rb, p53 or p73 facilitated the induction of apoptosis by TNF-a in AoSMCs. Towards this purpose, AoSMCs were transfected with siRNA to these proteins or a control siRNA, treated with TNF-a for 18 h and apoptosis assessed by TUNEL staining. Transfection of siRNAs to E2F1, ASK1, Rb, p53 or p73 caused an increase in the number of unstimulated cells that underwent apoptosis (Figure 5a ). At the same time, TNF-a stimulation did not induce significantly higher amount of apoptosis in any of these transfected cells. PARP cleavage (Figures 5c-g ) confirmed that there was no induction of apoptosis in AoSMCs upon TNF-a treatment even after transfection with these siRNAs. This suggests that although these genes are necessary for maintaining the survival of AoSMCs, these cells remain resistant to TNF-a-induced apoptosis.
Effect of siRNAs on TNF-a-induced proliferation of AoSMCs. As TNF-a was found to have a significant proliferative effect on AoSMCs, we examined whether absence of ASK1, E2F1, Rb, p53 or p73 affects its proliferative effect. AoSMCs were transfected with individual siRNAs and were treated with TNF-a (100 ng/ml) for 18 h before BrdU staining. Absence of E2F1 inhibited the proliferation of both untreated and TNF-a stimulated AoSMCs (Figure 5b ). Whereas depletion of ASK1, Rb, p53 and p73 reduced the number of BrdU-positive cells in both unstimulated and TNF-a stimulated cells, there was no significant effect on TNF-a -induced proliferation. This suggests that E2F1 mediates the TNF-a -induced proliferation of AoSMCs while other components of the ASK1-Rb-p73 pathway are not necessary for the proliferative effects of TNF-a.
TNF-a alters the promoter occupancy of E2F1 and Rb differently in HAECs and AoSMCs. Previous studies had shown that E2F1 can induce the transcriptional activity of p73P1 promoter.
29,30
We performed chromatin immunoprecipitation (ChIP) assays to ascertain how the occupancy of E2F1 is modulated on proliferative (cdc25A and TS) and apoptotic (p73) promoters upon TNF-a treatment. E2F1 occupied the proliferative cdc25A and TS promoters in untreated HAECs, whereas there was less E2F1 on the pro-apoptotic p73 promoter (Figure 6a ). TNF-a stimulation led to a progressive dissociation of E2F1 from the proliferative promoters; interestingly, there was a concomitant increase in the amount of E2F1 associating with the p73 promoter (Figure 6a ). The reverse was true for Rb: TNF-a treatment led to the progressive enrichment of Rb on the proliferative promoters, with a concomitant reduction in its association with the p73 promoter. As Rb inhibits the transcriptional activity of E2F1, this indicates a repression of Cdc25A and TS upon TNF-a treatment. Real-time PCR experiments showed that indeed TNF-a treatment led to a repression of both cdc25A and TS genes (Figures 6b and c) .
In contrast, TNF-a treatment led to the increased association of E2F1 with the cdc25A and TS promoters in AoSMCs, whereas Rb was dissociated from these promoters; there was no change in their binding to p73 promoter (Figure 6d ). Real-time Figure 4 TNF-a induces apoptosis in HAECs through p73a. Western blot analysis shows induction of p73a with TNF-a treatment, no change in p73b and reduction in DNp73a in untransfected HAECs (a). Western blot analysis shows silencing of p73a with p73 siRNA-2 and no change in p73b or DNp73a protein levels (b). HAECstransfected with control siRNA show an increase in p73a, no change in the p73b and reduction in DNp73a protein upon TNF-a stimulation. Abrogation of p73a with p73siRNA-2 transfection resulted in no change in p73a or p73b with TNF-a stimulation, at the same time DNp73a levels decreased (c). TUNEL assay shows induction of apoptotic cells upon TNF-a stimulation that is significantly reduced in the absence of p73a protein (d). Real-Time PCR showing p73a induction in the presence of TNF-a in the control siRNAtransfected HAECs. Depletion of p73a resulted in decrease in p73a in the presence and absence of TNF-a (e). There was no change in p73b mRNA upon TNF-a treatment in both control siRNA and p73siRNA-2
-transfected cells (f). Error bars indicate standard deviations (d-f) from two independent experiments
PCR experiments showed that TNF-a stimulation led to an induction of the E2F1-regulated cdc25A and TS genes (Figures 6e and f) , facilitating cell cycle progression. Thus, TNF-a appears to elicit differential effects on HAECs and AoSMCs through the mediation of E2F1.
Disruption of Rb-ASK1 interaction reduces TNF-ainduced apoptosis. As ASK1 kinase contributes to TNF-ainduced apoptosis, we assessed whether disruption of the ASK1-Rb interaction affected TNF-a-induced apoptosis in HAECs. ASK1 kinase is known to bind Rb through the canonical Rb-binding motif, LXCXE.
11 A 16-amino-acid peptide spanning the LXCXE motif of ASK1 was conjugated to a carrier peptide, penetratin, and delivered into HAECs using published protocols. 11 The ability of this conjugate to disrupt the ASK1-Rb interaction was tested by an immunoprecipitation-western blot experiment. TNF-a treatment resulted in robust binding of ASK1 to Rb; this interaction was reduced in cells that were TNF-a stimulated after transfection of the ASK1 peptide conjugate (Figure 7a ).
The effect of abrogating ASK1-Rb interaction on TNF-ainduced apoptosis was evaluated by TUNEL staining. Approximately 70 ± 4.7% (Po0.01) cells were apoptotic after treatment with TNF-a; however, in presence of ASK1-Penetratin peptide the apoptotic cells decreased by 22% (48±5.0%; Po0.01) (Figure 7b ). The unconjugated peptide did not influence the apoptotic effect of TNF-a on HAECs. This experiment suggests that the binding of ASK1 to Rb facilitates TNF-a-induced apoptosis in HAECs. ASK1 peptide conjugate had no significant effect on AoSMCs after TNF-a treatment (Figure 7c ).
Effect of disruption of Rb-ASK1 interaction on transcription of proliferative and apoptotic genes. ChIP assays were conducted to evaluate whether disruption of ASK1-Rb interaction affected the promoter occupancy for E2F1 and Rb in HAECs. Cdc25A and TS promoters were analyzed for the binding of E2F1 and Rb after delivering ASK1-Pen peptide. E2F1 was bound to both promoters in control (unstimulated) cells; treatment with TNF-a led to the displacement of E2F1 while Rb is enriched (Figure 8a ). Treatment with TNF-a in presence of ASK1-Pen peptide showed that a small amount of E2F1 still bound to both the proliferative promoters, probably because E2F1 competes with ASK1 peptide for binding to Rb. On the other hand, Rb occupies the p73 promoter while E2F1 binding is low in untreated cells; treatment with TNF-a reverses the situation, as E2F1 binds to the promoter while Rb is displaced. In presence of ASK1-Pen, treatment with TNF-a shows binding of a low amount of E2F1 while Rb is retained (Figure 8a) .
As inhibition of ASK1-Rb interaction could reverse the TNF-a-induced silencing of proliferative promoters, we measured the mRNA levels of TS by RT-PCR. It was found that there was a marked decrease in TS expression levels upon TNF-a treatment. However, the expression levels are rescued by treating the cells with ASK1-Pen simultaneously with TNF-a (Figure 8b) .
Discussion
In the case of atherosclerosis and related conditions, preservation of the endothelium with simultaneous inhibition of smooth muscle cell proliferation is beneficial to promote reendothelialization. 31 Migration, proliferation and differentiation of HAECs and AoSMCs are thus pathological responses that facilitate the development and progression of vascular lesions. 32 Cytokines such as TNF-a are present at sites of vascular injury and regulate HAECs and VSMCs by transducing signals to the nucleus, where multiple genes are regulated to participate in lesion formation through proliferation, differentiation and apoptosis. 33 Our studies had shown that upon TNF-a treatment, ASK1 mediates Rb inactivation in Ramos and Jurkat cells. 11 We observe similar response in HAECs, where Rb is inactivated upon TNF-a treatment, facilitating upregulation of the proapoptotic protein p73a. The role of p53 in TNF-a-induced apoptosis has been controversial. 34 We find that TNF-a had no effect on p53-mediated regulation of apoptosis in HAECs; however, ASK1 and p73 levels were found to be upregulated. We found an increase in ASK1 kinase activity with TNF-a stimulation in HAEC cells, and depletion of p73a inhibited TNF-a-induced apoptosis, implicating ASK1 and p73a to be the major contributing factors to endothelial cell apoptosis. The silencing of ASK1, E2F1 and p73 rescued HAECs from TNF-a-induced apoptosis, whereas silencing of Rb and p53 increased apoptosis suggesting an E2F1 regulated apoptotic pathway in these cells. Additionally, we found the p73a, and not p73b or DNp73a, to be the main mediator of apoptosis. ChIP and RT-PCR results confirm that more E2F1 is recruited on p73 promoter while it is lost from proliferative promoters upon exposure to TNF-a. The use of peptide corresponding to the LXCXE domain of ASK1 was able to decrease the recruitment of E2F1 on p73 promoter.
A very contrasting observation was made in AoSMCs; there was no effect of TNF-a on ASK1, p53 and p73 levels, and reduced ASK1 kinase activity suggests a lack of apoptotic response. In contrast we observed an increase in levels of pMEK and pERK (data not shown) and a simultaneous decrease in pp38 and pJNK suggesting a proliferative response in AoSMC cells. It has been shown that colocalization of TNF-a and ERK1/2 occurs leading to the expression of Ets-1, Egr-1 and c-Fos in neointimal lesions from rat aortae 2 weeks post balloon injury. 35 The ChIP and RT-PCR experiments showed recruitment of E2F1 to proliferative promoters and increased expression of cdc25A and TS genes, respectively.
Although Rb interacts with ASK1 upon apoptotic stimuli, the Raf-1 kinase binds to Rb in response to proliferative signals, facilitating its inactivation.
14 Thus, selective Rb phosphorylation by different kinases facilitates apoptotic or proliferative pathways in response to specific signaling events. 36 The divergent responses of AoSMCs and HAECs to TNF-a provide unique therapeutic possibilities to target two different cell types simultaneously within the same tissue microenvironment, resulting in opposite but complimentary effects. It can be imagined that modulators of the Rb function might be good candidates for this purpose.
Materials and Methods
Cell culture and treatment. HAECs were grown in EGM medium (EBM2 þ bullet kit) from Lonza (Basel, Switzerland). AoSMCs were grown in SMGM medium (SMBM þ bullet kit) from Lonza.
Antibodies. Polyclonal E2F1 (cat no. sc-50, for ChIP assay), monoclonal E2F1 (cat no. sc-251, for western blotting), polyclonal Rb (cat no.; sc-193, for ChIP assay), polyclonal ASK1 (cat no. sc-7931), polyclonal JNK (cat no. sc-474), monoclonal p73 (cat no. sc-17823), monoclonal p73a (cat no. sc-56194), monoclonal p53 (cat no. sc-263) antibodies were purchased from Santa Cruz biotechnology, Santa Cruz, CA, USA. Polyclonal phospho-p38 MAPK (cat no. 9211), polyclonal phospho-p53 (Ser46) (cat no. 2521), polyclonal p38 MAPK (cat no. 9212), polyclonal PARP (cat no. 9542), were purchased from Cell Signaling Technology, Danvers, MA, USA. Monoclonal beta-actin Clone AC-1 (cat no. A1978) was from Sigma-Aldrich, St. Louis, MO, USA. Monoclonal Rb (cat no. 554136) was purchased from BD Pharmingen, Franklin Lake, NJ, USA. Monoclonal p73b (cat no. ab33131) was from Abcam (Cambridge, MA, USA) and monoclonal DNp73a (cat no. IMG-313A) was obtained from Imgenex, San Diego, CA, USA. si RNA transfections. ASK1 (cat no. sc-29748), E2F1 (cat no. sc-29297), p53 (cat no. sc-29435), p73 (cat no.sc-36167), Rb (cat no. sc-29468) and control non-homologous (cat no. sc-37007) siRNAs were obtained from Santa Cruz Biotechnology. p73 siRNA-2 was custom synthesized from Integrated DNA Technologies (San Diego, CA, USA) (sequence: 5 0 -UCU GCU GAG CAG CAC CAU G-3 0 , used at 200 pmol concentration). 37 All the other siRNAs were used at 100 pmoles concentration. The transfections were performed in HAEC and AoSMC cells using Oligofectamine (Invitrogen, Carlsbad, CA, USA). The treatment of cells with TNF-a (100 ng/ml) was started 24 h after transfections, for an additional 18 h. The cells were then subjected to TUNEL assays or BrdU proliferation assays, or western blotted for PARP, E2F1, ASK1, Rb, p53, p73a and actin. The western blots for each protein were run separately.
ASK1 in vitro kinase assay. ASK1 kinase assay was performed according to the protocol previously described. 11 HAEC or AoSMC cells were untreated or treated with 100 ng/ml TNF-a for 30 min, 2 or 18 h. The cells were washed twice with cold PBS containing 1 mM sodium orthovanadate and lysed in nonionic lysis buffer. Immunoprecipitations were carried out using 200 mg protein and 1 mg of anti-rabbit ASK1 antibody. Myelin basic protein (Sigma) was used as substrate for ASK1. Immunobeads were subjected to kinase reaction in a total volume of 30 ml containing 20 mM MgCl 2 , 0.1 M sodium orthovanadate, 1 M dithiothreitol, 30 mM b-glycerol phosphate, 5 mM EGTA, 20 mM MOPS, 1 mM ATP, 10 mg of substrate/ sample and 2.5 mCi of [g- 32 P]ATP/sample. The samples were incubated at 301C for 30 min. The reactions were terminated by the addition of sample buffer. The protein samples were separated on a 12% SDS-PAGE gel, transferred to a nitrocellulose membrane, and subjected to autoradiography. The blot was then stained with Ponceau (Bio-Rad Laboratories, Hercules, CA, USA) for myelin basic protein and was also probed with ASK1 polyclonal antibody for equal protein loading. The assay was repeated three times with three independent lysates for each cell line.
p38 and JNK western blotting. HAEC and AoSMC cells were treated with 100 ng/ml TNF-a for 0, 5, 10 and 15 min. 50 mg lysates were run on 10% SDS-PAGE, transferred onto nitrocellulose membrane and immunoblotted for phosphop38 (Thr180/Tyr182), p38 MAPK, phospho-JNK (Thr183/Tyr185), JNK and actin.
Immunoprecipitation and immunoblotting. Cell lysates (50-200 mg) were treated with 1 mg of the appropriate primary antibody in a volume of 100 ml at 41C for 1 h. A 3 mg aliquot of protein G-Sepharose in a 100 ml volume was added to each sample and incubated for an additional hour. The binding was performed in a buffer containing 20 mM HEPES, pH 7.9, 40 mM KCl, 1 mM MgCl 2 , 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM dithiothreitol, 0.1 mM NaF, 0.1 mM Na 3 VO 4 , 0.5% Igepal and 3 mg of bovine serum albumin per ml. The beads were washed six times with 600 ml of the same buffer, boiled in 20 ml of SDS sample buffer and separated on 8 or 10% polyacrylamide gels. After semi-dry transfer to supported nitrocellulose membranes, the blots were probed with the appropriate antibody. The proteins were detected by using an enhanced chemiluminescence assay system from Amersham Biosciences (Piscataway, NJ, USA).
ChIP assay. ChIP assay was performed using two confluent plates of HAECs or AoSMCs (about 1 Â 10 6 cells per plate) for each immunoprecipitation reaction, as described previously. 11 Briefly, cells were cross-linked with 1% formaldehyde for 20 min at room temperature; the cells were harvested and lysates were prepared. The Rb polyclonal and E2F1 polyclonal antibodies were used for immunoprecipitations. HA antibody IP was used as negative control. Immuneprecipitates were analyzed for the presence Rb and E2F1 on cdc25A, TS and p73 promoter. Rabbit anti-mouse secondary antibody was used as the control for all reactions. The PCR were then performed using 5 ml of the DNA from the immunoprecipitation reactions or 1 ml of DNA from the input reaction as template. PCR cycling conditions were as follows: 941C for 2 min; then 35 cycles of 941C for 30 s, 561C (Cdc25a, fos, TS)/531C (for p73) for 30 s and 681C for 30 s, followed by 681C for 2 min. The sequences of the PCR primers used in the PCR reactions were as follows:
p73 promoter (forward primer) 5 0 -GCCGGGAGGAGACCTTGG-3 0 ; p73 promoter (reverse primer) 5 0 -GTTTCGCTGCGTCCCCTTCG-3 0 ; Cdc25A promoter (forward primer) 5 0 -TCTGCTGGGAGTTTTCATTGACCTC-3 0 ; Cdc25A promoter (reverse primer) 5 0 -TTGGCGCCAAACGGAATCCACCAATC-3 0 ; TS promoter (forward primer) 5 0 -TGGCGCACGCTCTCTAGAGC-3 0 ; TS promoter (reverse primer) 5 0 -GACGGAGGCAGGCCAAGTG-3 0 ; c-Fos promoter (forward primer) 5 0 -TGTTGGCTGCAGCCCGCGAGCAGTTC-3 0 ; c-Fos promoter (reverse primer) 5 0 -GGCGCGTGTCCTAATCTCGTGAGCAT-3 0 .
RNA isolation. HAECs and AoSMCs were treated with TNF-a. Unstimulated asynchronous cells were used as control. Total RNA was isolated by RNeasy miniprep kit (cat no. 74104) from Qiagen (Valencia, CA, USA) following the manufacturer's protocol.
Real-time PCR. RT-PCR was performed using one confluent plate of HAECs for each treatment. One mg RNA was DNase-treated using RQ1 DNase (Promega), followed by first-strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad). 1/20th of the final cDNA reaction volume was used in each PCR reaction. Primers sequences are as follows: TS (forward primer) 5 0 -CTGCCAGCTGTACCAGAGAT-3 0 ; TS (reverse primer) 5 0 -ATGTGCATCTCCCAAAGTGT-3 0 ; Cdc25A (forward primer) 5 0 -AACCTGACCGTCACTATGGA-3 0 ; Cdc25A (reverse primer) 5 0 -GAATCTGTTGACTCGGAGGA-3 0 ; b-actin (forward primer) 5 0 -ATCCTCACCCTGAAGTACCC-3 0 ; b-actin (reverse primer) 5 0 -TAGAAGGTGTGGTGCCAGAT-3 0 . All primers were run at an annealing temperature of 581C. Real-time PCR reactions were performed in a volume of 25 ml, which included 200 nM of each forward and reverse primer and iQ SYBR Green Supermix (Bio-Rad). Reactions were run in duplicate using an iCycler and iQ software (Bio-Rad). Average threshold cycles (Ct) for TS and Cdc25A were normalized to the average b-actin Ct values for each cDNA sample and relative levels of p73, TS and Cdc25A were calculated by the DDCt method: 38 2 ÀTSÀb-actin for TS expression or 2 ÀCdc25aÀb-actin for Cdc25a expression. Fold-change was determined and plotted as histograms.
Similarly, Real-Time PCR was performed for p73a and b. 39 RNA was made from HAECs transfected with 200 pmol each of either control siRNA or p73a siRNA followed by treatment with TNF-a for 18hr. The primers used were as follows: p73a (forward primer) 5 0 -GCACCACGTTTGAGCACCTCT-3 0 ; p73a (reverse primer) 5 0 -GCAGATTGAACTGGGCCATGA-3 0 ; p73b (forward primer) 5 0 -CCGACCCCAGCCTCGTCAG-3 0 ; p73b (reverse primer) 5 0 -CTGAGCCGCCGATGGA-3 0 . The primers were run at an annealing temperature of 601C. The rest of the protocol remained as described above.
Delivery of ASK1 peptide to cells. We have synthesized a peptide corresponding to the LXCXE domain of ASK1 (AKAFILKCFEPDPDKRAC), which is essential for binding to Rb with a cysteine residue added at the C terminus for coupling to the carrier molecule, penetratin. 40 10 mM ASK1 peptide was conjugated to 1 mM penetratin (QBiogene, Carlsbad, CA, USA) in the presence of 10 mM tris-(2-carboxyethyl) phosphine as described previously. 40 The final conjugate was diluted to 150 mM and aliquoted and stored in À801C until further use. Approximately 10 000 HAECs will be plated on eight-well poly-D-lysine-coated chamber slides; the cells were treated with TNF-a (100 ng/ml) for 18 h in the presence or absence of 5 mM ASK1 peptide conjugated to penetratin. For the negative control, cells were exposed to the same concentration of unconjugated peptide. The effect of abrogation of interaction of Rb and ASK1 on apoptosis of HAECs was evaluated by TUNEL assay and assessing PARP cleavage in the lysates.
Statistical and densitometric analysis. For all data shown, Student's t-test was conducted to evaluate for differences among control and TNF-a treatments and Pr0.05 was considered significant. Data shown are mean±S.D. Densitometric analysis was done on the western blots as indicated using AlphaEaseFC software and the fold-change was determined.
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